

## Review questions and outcomes

**Table 1: Review questions for guideline update**

Chapter	Review questions	Outcomes
<b>Diagnosis</b>	<p>In a person with suspected clinical OA (including knee pain) when would the addition of imaging be indicated to confirm additional or alternative diagnoses (particularly to identify red flags) such as:</p> <ul style="list-style-type: none"> <li>-Crystal arthritis (gout or CPPD)</li> <li>-Inflammatory arthritis (including rheumatoid arthritis, psoriatic arthritis)</li> <li>-Infection</li> <li>-Cancer, usually secondary metastases</li> </ul>	<ul style="list-style-type: none"> <li>• Sensitivity</li> <li>• Specificity</li> <li>• Likelihood ratio</li> <li>• Diagnostic accuracy</li> <li>• Other clinical management outcomes (e.g. referral)</li> </ul>
<b>Acupuncture</b>	<p>What is the clinical and cost effectiveness of acupuncture versus sham treatment (placebo) and other interventions in the management of osteoarthritis?</p>	<ul style="list-style-type: none"> <li>• Global joint pain (WOMAC, VAS, or NRS pain subscale, WOMAC for knee and hip only, AUSCAN subscale for hand)</li> <li>• Function (WOMAC function subscale for hip or knee or equivalent such as AUSCAN function subscale or Cochin or FIHOA for hand and change from baseline)</li> <li>• Stiffness (WOMAC stiffness score change from baseline)</li> <li>• Time to joint replacement</li> <li>• Quality of life (EQ5D, SF 36)</li> <li>• Patient global assessment</li> <li>• OARSI responder criteria</li> <li>• Adverse events</li> </ul>

Chapter	Review questions	Outcomes
		<ul style="list-style-type: none"> <li>• Measure Yourself Medical Outcome Profile</li> </ul>
<b>Nutraceuticals</b>	What is the clinical and cost effectiveness of glucosamine and chondroitin alone or in compound form versus placebo or other treatments in the management of osteoarthritis?	<ul style="list-style-type: none"> <li>• Global joint pain (VAS, NRS or WOMAC pain subscale, WOMAC for knee and hip only, AUSCAN subscale for hand)</li> <li>• Function (WOMAC function subscale for hip or knee or equivalent such as AUSCAN function subscale or Cochin or FIHOA for hand and change from baseline)</li> <li>• Stiffness (WOMAC stiffness score change from baseline)</li> <li>• Structure modification</li> <li>• Time to joint replacement</li> <li>• Quality of life (EQ5D, SF 36)</li> <li>• Patient global assessment</li> <li>• OARSI responder criteria</li> <li>• Adverse events (GI, renal and cardiovascular)</li> </ul>
<b>Hyaluronan Injections</b>	What is the clinical and cost effectiveness of intra-articular injections of hyaluronic acid/ hyaluronans in the management of OA in the knee, hand, ankle, big toe and hip?	<ul style="list-style-type: none"> <li>• Global joint pain (VAS or NRS, WOMAC pain subscale, WOMAC for knee and hip only, AUSCAN for hand)*</li> </ul>

Chapter	Review questions	Outcomes
		<ul style="list-style-type: none"> <li>• Function (WOMAC function subscale for hip or knee or equivalent such as AUSCAN function subscale and change from baseline)</li> <li>• Stiffness (WOMAC stiffness score change from baseline)</li> <li>• Time to joint replacement</li> <li>• Minimum joint space width</li> <li>• Quality of life (EQ5D, SF 36)*</li> <li>• Patient global assessment</li> <li>• OARSI responder criteria</li> <li>• Adverse events*</li> <li>• -post injection flare</li> </ul>
<b>NSAIDs/COX 2 Inhibitors</b>	<p>What is the clinical and cost effectiveness of Etoricoxib 30mg in the management of osteoarthritis?</p> <p>What is the clinical and cost effectiveness of fixed-dose combinations of NSAIDs/cox 2 inhibitors + GPA in the management of osteoarthritis?</p>	<ul style="list-style-type: none"> <li>• Global joint pain (WOMAC, VAS, or NRS pain subscale, WOMAC for knee and hip only, AUSCAN subscale for hand)</li> <li>• Function (WOMAC function subscale for hip or knee or equivalent such as AUSCAN function subscale or Cochin or FIHOA for hand and change from baseline)</li> </ul>

Chapter	Review questions	Outcomes
		<ul style="list-style-type: none"> <li>• Stiffness (WOMAC stiffness score change from baseline)</li> <li>• Time to joint replacement</li> <li>• Quality of life (EQ5D, SF 36)</li> <li>• Patient global assessment</li> <li>• OARSI responder criteria</li> <li>• Compliance/adherence</li> <li>• Adverse events (GI, CV and renal)</li> </ul>
<b>Paracetamol</b>	<p>What is the efficacy and adverse events profile of paracetamol when compared to placebo in the management of osteoarthritis?</p> <p>Which are the adverse events in an OA population with the use of paracetamol in the management of osteoarthritis?</p> <p>Which are the adverse events in a general population with the use of paracetamol?</p>	<p>Efficacy</p> <ul style="list-style-type: none"> <li>• Global joint pain (WOMAC, VAS, or NRS pain subscale, WOMAC for knee and hip only, AUSCAN subscale for hand)</li> <li>• Function (WOMAC function subscale for hip or knee or equivalent such as AUSCAN function subscale or Cochin or FIHOA for hand and change from baseline)</li> <li>• Stiffness (WOMAC stiffness score change from baseline)</li> <li>• Time to joint replacement</li> <li>• Quality of life (EQ5D, SF 36)</li> <li>• Patient global</li> </ul>

Chapter	Review questions	Outcomes
		<p>assessment</p> <ul style="list-style-type: none"> <li>• OARSI responder criteria</li> </ul> <p>Adverse events:</p> <p><i>Gastro-intestinal</i></p> <ul style="list-style-type: none"> <li>• Admissions/Deaths with serious GI bleeds</li> <li>• Anaemia (iron deficiency)</li> <li>• Gastric/duodenal ulceration</li> <li>• Bowel perforations</li> </ul> <p><i>Cardiovascular</i></p> <ul style="list-style-type: none"> <li>• Increased incidence of ischaemic heart disease/myocardial infarction</li> <li>• Increased incidence of hypertension</li> <li>• Heart failure</li> <li>• Stroke</li> </ul> <p><i>Renal</i></p> <ul style="list-style-type: none"> <li>• Increased incidence of hypertension</li> <li>• Acute tubular necrosis or acute renal failure</li> <li>• Chronic kidney disease or chronic renal failure</li> </ul>
<b>Decision-aids</b>	What is the clinical and cost-effectiveness of decision aids in the management of OA?	<ul style="list-style-type: none"> <li>• Attributes of the choice</li> <li>• Attributes of the decision making process</li> <li>• Decisional conflict</li> <li>• Patient-practitioner communication</li> <li>• Participation in decision making</li> </ul>

Chapter	Review questions	Outcomes
		<ul style="list-style-type: none"> <li>• Proportion undecided</li> <li>• Satisfaction</li> <li>• Choice (actual choice implemented, option preferred as surrogate measure)</li> <li>• Adherence to chosen option</li> <li>• Health status and quality of life (generic and condition specific)</li> <li>• Anxiety, depression, emotional distress, regret, confidence</li> <li>• Consultation length</li> </ul>
<b>Follow-up</b>	<p>What is the clinical and cost effectiveness of regular follow-up/review in reinforcing core treatments (information, education, exercise, weight reduction) care in the management of OA?</p> <p>Which patients with OA will benefit the most from reinforcement of core treatment as part of regular follow-up/review?</p>	<ul style="list-style-type: none"> <li>• Global joint pain (WOMAC, VAS, or NRS pain subscale, WOMAC for knee and hip only, AUSCAN subscale for hand)</li> <li>• Function (WOMAC function subscale for hip or knee or equivalent such as AUSCAN function subscale or Cochin or FIHOA for hand and change from baseline)</li> <li>• Stiffness (WOMAC stiffness score change from baseline)</li> <li>• Time to joint replacement</li> </ul>

Chapter	Review questions	Outcomes
		<ul style="list-style-type: none"> <li>• Quality of life (EQ5D, SF 36)</li> <li>• Patient global assessment</li> <li>• OARSI responder criteria</li> <li>• Improvement in depression/psychological outcomes</li> </ul>
<b>Timing of surgery</b>	What information should people with OA receive to inform consideration of the appropriate timing of referral for surgery as part of their OA management?	<ul style="list-style-type: none"> <li>• Patient views/experiences</li> <li>• Patient preference/satisfaction</li> <li>• Patient knowledge</li> </ul>